Sort by
Keyphrases
Adverse Drug Reaction
24%
Adverse Effects
14%
Antibiotics
24%
Antiviral Agents
24%
Azithromycin
43%
B Vitamin Supplementation
24%
Bacterial Infection
24%
Baumannii
22%
Carbapenem-resistant Acinetobacter Baumannii
24%
Carbapenems
20%
Clinical Impact
24%
COVID-19
39%
COVID-19 Cases
12%
COVID-19 Infection
24%
COVID-19 Patients
13%
Critically Ill COVID-19 Patients
24%
Doxycycline
34%
Drug Combination
49%
Dual Drug
27%
Hematopoietic Stem Cells
24%
Hospitalized Patients
49%
Hydroxychloroquine
53%
In Vitro Study
49%
Indonesia
100%
Intensive Phase
24%
Interleukin-12 (IL-12)
24%
Lopinavir
53%
Moderate COVID-19
24%
Multicenter Clinical Trial
24%
Multidrug Resistance
24%
Multidrug-resistant
24%
Multidrug-resistant Tuberculosis (MDR-TB)
28%
Natural Killer Cells
34%
Patients with COVID-19
24%
Pneumonia
24%
Pulmonology
24%
Randomized Double-blind
24%
Randomized Trial
24%
Referral Hospital
24%
Remdesivir
24%
Rifampicin-resistant Tuberculosis
24%
SARS-CoV-2 Virus
39%
Shorter Regimen
24%
Surabaya
74%
Tuberculosis Patients
34%
Tuberculosis Treatment
24%
Updated Meta-analysis
24%
Viral Inactivation
24%
Viral Load
13%
Vitamin B1
19%
Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter Baumannii
24%
Adverse Drug Reaction
24%
Antibiotics
26%
Antivirus Agent
24%
Azithromycin
43%
Bacterial Infection
24%
Carbapenem
24%
Clarithromycin
6%
Clinical Study
24%
Cohort Study
29%
Combination Drug
49%
Combination Therapy
6%
Cytotoxicity
9%
Diseases
6%
Doxycycline
34%
Drug Resistant Tuberculosis
24%
Extensively Drug-Resistant Tuberculosis
24%
Favipiravir
9%
Hydroxychloroquine
53%
IC50
6%
Infection
56%
Interleukin 10
7%
Interleukin 12
24%
Interleukin 6
7%
Lopinavir Plus Ritonavir
49%
Mixed Infection
24%
Multi-Drug-Resistant Tuberculosis
37%
Multidrug Resistance
24%
Pharmacotherapy
6%
Prevalence
10%
Pyridoxine
9%
Quinolone Derivative
24%
Remdesivir
24%
Respiratory Failure
5%
Retrospective Study
24%
Rifampicin
24%
SARS Coronavirus
49%
Side Effect
24%
Thiamine
19%
Treatment Group
6%
Tumor Necrosis Factor
7%
Vitamin B Group
24%
Vitamin B12
19%
Medicine and Dentistry
Acinetobacter Baumannii
24%
Bacterial Infection
16%
Carbapenem
24%
Cohort Analysis
24%
COVID-19
49%
Intensive Care
5%
Meta-Analysis
24%
Mixed Infection
24%
Patient Referral
24%
Remdesivir
24%
Respiratory Medicine
24%